|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abbott Laboratories, of Abbott Park, Ill., said the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, issued a positive opinion recommending Humira's (adalimumab) approval in psoriatic arthritis and as first-line treatment for moderate to severe early rheumatoid arthritis.
o Aeolus Pharmaceuticals Inc., of Research Triangle Park, N.C., said Xmark Opportunity Funds and other investors, including the Biotechnology Value Fund LP, agreed to provide up to $2.5 million in funding in the form of convertible preferred stock and warrants. The funds are being provided primarily for animal testing and development of ...